BCS vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Barclays PLC (BCS) exhibits weak financial health with a Piotroski F-Score of just 2/9, indicating significant fundamental deterioration. Despite strong recent price performance and a low forward P/E of 8.96, the stock trades above both the Graham Number ($17.26) and intrinsic value estimate ($15.26), suggesting overvaluation. Profitability margins are strong, but ROA is extremely low at 0.44%, and earnings growth is negative both year-over-year and quarter-over-quarter. Combined with bearish insider activity and weak technical trend scores, the risk-reward profile is unattractive.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
BCS vs JPM: Head-to-Head Comparison
This page compares Barclays PLC (BCS) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.